A practical reference on Semax: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-04-26. Anything still debated is marked as such rather than presented as settled.
Development is attributed to researchers at the Institute of Molecular Genetics in Moscow during the early 1980s, building on earlier Soviet work with ACTH fragments. Russian regulatory approval followed for intranasal use, and the compound has remained commercially available there for decades. Most published human data originate from Russian and, later, some Eastern European clinical reports, which are not always accessible in English translation. Outside that region the material is generally handled as a research chemical rather than a licensed medicine.
Regulatory status differs sharply between jurisdictions. In Russia the peptide is registered as a prescription nasal preparation, while agencies such as the United States Food and Drug Administration have not approved it for any indication. Products sold elsewhere are typically labeled for laboratory research only, and such labels shift responsibility for safe handling to the purchaser. Because the same name covers pharmaceutical-grade nasal drops and bulk research powder, identity and purity documentation becomes the main practical concern when comparing sources.
Later generations of the molecule include an N-acetylated form and an amidated form, both marketed online alongside the parent peptide. These variants differ in terminal chemistry and stability, and they are frequently discussed in the same breath even though they have not been compared in controlled trials. Supply outside formal healthcare systems comes largely from laboratories that synthesize peptides to order. Purity and identity of these materials vary widely, and no single body oversees the international trade.
Semax is a synthetic heptapeptide developed in the Soviet Union during the 1980s by researchers at the Institute of Molecular Genetics in Moscow. It was designed as a truncated analog of adrenocorticotropic hormone, retaining only the fragment spanning residues four through ten. Investigators sought a peptide that would preserve the cognitive effects associated with ACTH while eliminating the hormonal stimulation of the adrenal cortex. The compound entered clinical use in Russia during the following decade.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide (ACTH fragment analog) | Not a steroid; does not belong to the melanocortin agonist drugs by marketing category |
| Molecular formula | C37H51N9O10S (commonly cited) | Reported values vary slightly with salt and counter-ion content |
| Appearance | White to off-white lyophilized powder | A single batch may appear as a loose cake or fluffy solid |
| Solubility | Freely soluble in water and aqueous buffer | Stock solutions are usually prepared in sterile water or saline |
| Typical storage | −20 °C or below, desiccated and protected from light | Seal opened vials promptly to limit moisture uptake |
The compound was developed during the 1980s at the Institute of Molecular Genetics in Moscow as part of research on fragments of adrenocorticotropic hormone. Early work examined short ACTH-derived sequences that retained neurotrophic effects while lacking the endocrine activity of the full hormone. Semax entered clinical use in Russia during the 1990s, where it received registration for several neurological indications. Outside that region it remained primarily a laboratory research material rather than an approved therapeutic. English-language literature on it grew more slowly and frequently cited the original Russian studies.
Terminology around the compound varies by source. It appears in catalogues and papers as Semax, as the heptapeptide ACTH(4-7)-Pro-Gly-Pro, and under various alphanumeric laboratory codes used by individual suppliers. These names refer to the same sequence but may imply different salt forms, purity grades, or counter-ions. Peptide databases usually list the free base mass, while product descriptions sometimes report acetate or trifluoroacetate salts with a different formula weight. Because naming conventions for research peptides are not standardised across vendors, checking the declared sequence and measured mass is more reliable than relying on a trade name alone.
Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.
The parent fragment ACTH(4-10) carries the sequence Met-Glu-His-Phe-Arg-Trp-Gly. Semax replaces the arginine and tryptophan positions with a proline-glycine-proline tail, giving Met-Glu-His-Phe-Pro-Gly-Pro. That change removes residues associated with adrenal stimulation, so the peptide does not drive cortisol release the way full ACTH does. This distinction shapes how the compound is grouped in the literature, where it sits with neuropeptides and peptide neuromodulators rather than with corticosteroids.
Semax 是一种人工合成的七肽，氨基酸序列为 Met-Glu-His-Phe-Pro-Gly-Pro，单字母缩写记作 MEHFPGP。它被归类为促肾上腺皮质激素片段 ACTH(4-10) 的结构类似物，但并不天然存在于生物体内。母体片段 ACTH(4-10) 的序列为 Met-Glu-His-Phe-Arg-Trp-Gly，Semax 替换了中间两个残基，并在羧基端延长了 Pro-Gly-Pro 三肽。这种延长被普遍认为能提升分子对肽酶的耐受性。
该化合物于二十世纪八十年代在俄罗斯被开发，相关工作由俄罗斯科学院分子遗传学研究所的研究团队主导。开发目标并非复制 ACTH 的完整激素活性，而是寻找保留其神经作用方向、同时去除促肾上腺皮质激素释放效应的短肽片段。研究记录显示，这一方向促成了多个相关短肽的合成与筛选，而 Semax 是其中被研究最广泛的一个。当地文献常以 Семакс 这一名称指代它。
研究兴趣主要集中在神经营养因子相关的路径上，包括脑源性神经营养因子与神经生长因子的表达变化。部分实验报告称在特定条件下观察到这些因子的水平上升，但具体信号通路和剂量依赖关系仍未完全厘清。多数公开数据来自细胞模型和动物实验，人体对照研究数量有限。因此，该化合物的作用机制在文献中属于活跃讨论，而非已经确立的定论。
It was given the name "tocopherol" from the Greek words "τόκος" [tókos, birth], and "φέρειν", [phérein, to bear or carry] meaning in sum "to carry a pregnancy," with the ending "-ol" signifying its status as a chemical alcohol. George M. Calhoun, Professor of Greek at the University of California, was credited with helping with the naming process. Erhard Fernholz elucidated its structure in 1938 and shortly afterward the same year, Paul Karrer and his team first synthesized it. It was known since the 19th century that certain plants contain substances that prevent fat from going rancid. In 1937, it was found that vitamin E was specifically responsible for this. This led to the hypothesis that vitamin E's mechanism of action is as an antioxidant that prevents pathogenic oxidation of lipid and lipoprotein, specifically in biological membranes. Nearly 50 years after the discovery of vitamin E, an editorial in the Journal of the American Medical Association titled "Vitamin in search of a disease" read in part "...research revealed many of the vitamin's secrets, but no certain therapeutic use and no definite deficiency disease in man." The animal discovery experiments had been a requirement for successful pregnancy, but no benefits were observed for women prone to miscarriage. Evidence for vascular health was characterized as unconvincing. The editorial closed with mention of some preliminary human evidence for protection against hemolytic anemia in young children. A role for vitamin E in coronary heart disease was first proposed in 1946 by Evan Shute and colleagues.
Harry Emerson. For services to the community in Stockton-on-Tees, Cleveland. Elizabeth Margaret Evans. For services to the community, particularly Disabled People, in Llanelli, Dyfed. Shirley Everett, Newsvendor. For services to the community in Westminster, London. Doris Mabel Eves. For services to the Citizens' Advice Bureau in Farnborough, Hampshire. George Fitton Exley, Honorary Secretary, Scarborough Lifeboat Station. For services to the Royal National Lifeboat Institution. Ellen Branker Farmer, President, Old Paisley Society. For services to Conservation. Margaret Winifred Farmer. For services to the Royal British Legion in Sevenoaks, Kent. Eric Arnold Faux. For services to disabled people in Birmingham Valerie Ann Fea, lately Executive Secretary, the School Library Association. For services to Librananship and to Young People. Heather Duncan Findlay, Local Officer 2, the Benefits Agency, Department of Social Security. Nina Mary Fineron, lately Typist, Department of Social Security. Isabel H. Finlay, lately Chiropodist, Glasgow. For services to Health Care. Millar Henry Finlay, Divisional Officer, (Special Constabulary), Flintshire Division, North Wales Police. For services to the Police. Olwen Finlay. For services to Physiotherapy. Evelyn May Fisher. For services to Netball in Coventry. Myra Caroline Fisher. For services to the community in Paulsgrove, Portsmouth, Hampshire. Bernard Joseph Fitzsimmons. For public service. Michael Robert Flegg, Catering Manager, Nottingham City Hospital. For services to Health Care. Iris Mary Fletcher.
On 27 April 2022, Zardari was sworn in as Foreign Minister of Pakistan under Prime Minister Shehbaz Sharif following the removal of Imran Khan from the premiership amidst a constitutional crisis. President Arif Alvi administered his oath of office. At 33 years old, he became the youngest foreign minister in Pakistan's history. Upon assuming office, Bhutto Zardari outlined a foreign policy centred on “peace through dialogue,” economic diplomacy, and the revitalisation of Pakistan’s global image. During his first month in office, he visited China to discuss the advancement China–Pakistan Economic Corridor, and he met with his counterpart, Wang Yi. In September 2022, he visited the United States and met with U.S. Secretary of State Antony Blinken in Washington, D.C. to commemorate the 70th anniversary of Pakistan-U.S. diplomatic relations.
December 28, 1967: Authorization of contraception by the Neuwirth Law; however, its implementation decrees would not be published until 1971. January 24, 1968: Decree on common provisions applicable to civil servants in the active services of the national police: unless an exception is made, a woman cannot be appointed to a position within the active services. May 24, 1969: Decree setting the amount of the single salary allowance and the stay-at-home mother's allowance. June 4, 1970: In the Civil Code, "joint parental authority" replaces "paternal authority," and "both spouses jointly ensure the moral and material guidance of the family." July 15, 1970: Law concerning the École Polytechnique, which notably allows women to take the entrance exam and sets the conditions for their employment after graduation. August 26, 1970: Founding of the Women's Liberation Movement (MLF), marked by the laying of a wreath "to the wife of the unknown soldier" on the Tomb of the Unknown Soldier beneath the Arc de Triomphe in Paris. December 23, 1970: Decree increasing the rate of daily rest allowances for maternity insurance under the general social security system. April 5, 1971: Publication of the "Manifesto of the 343" in Le Nouvel Observateur: signed by 343 women — including celebrities — declaring they had undergone an abortion and demanding the right to free abortion. April 16, 1971: Ministerial order regarding the Women's Work Committee, replacing the Study and Liaison Committee on Women's Work Issues. June 10, 1971: Law on parentage.
=== Clinical attachment level === The clinical attachment level (CAL) combines the measurements of probing pocket depth and any gingival recession to give an overall indication of where the periodontal tissues attach to the root surface. It is measured from a constant reference point, usually the CEJ, to the base of the periodontal pocket. Due to the more stable and reproducible property, this is considered the best measure of changes in residual periodontal support over time.
Sources: en.wikipedia.org
=== Recovery === Before initiating any form of physical activity, the individual must demonstrate a normal level of functioning with all previous symptoms absent. Physical activity should be supervised by a health care professional in case of a recurrence. However, in some low-risk individuals, supervision by a medical professional is not required as long as the individual follows up with weekly checkups. Proper hydration prior to performing physical activity and performing exercise in cool, dry environments may reduce the chances of developing a reoccurring episode of ER. Lastly, it is imperative for urine and blood values to be monitored along with careful observation for the redevelopment of any signs or symptoms. The recovery program focuses on progressive conditioning/reconditioning the individual and improving functional mobility. However, special considerations prior to participating in the rehabilitation program include the individual's 1) extent of muscle injury, if any 2) level of fitness before the incident and 3) weight training experience. These special considerations collectively are a form of assessing the individual's capacity to perform physical activity, which is ultimately used to specify the ExRx design.
The flow of heat is governed by equations that are similar to the wave equation used to characterize sound propagation in air. When heat is introduced, it moves at 20 meters per second at 1.8 K through helium II as waves in a phenomenon known as second sound. Helium II also exhibits a creeping effect. When a surface extends past the level of helium II, the helium II moves along the surface, against the force of gravity. Helium II will escape from a vessel that is not sealed by creeping along the sides until it reaches a warmer region where it evaporates. It moves in a 30 nm-thick film regardless of surface material. This film is called a Rollin film and is named after the man who first characterized this trait, Bernard V. Rollin. As a result of this creeping behavior and helium II's ability to leak rapidly through tiny openings, it is very difficult to confine. Unless the container is carefully constructed, the helium II will creep along the surfaces and through valves until it reaches somewhere warmer, where it will evaporate. Waves propagating across a Rollin film are governed by the same equation as gravity waves in shallow water, but rather than gravity, the restoring force is the van der Waals force. These waves are known as third sound.
==== Metabolic block ==== Nerve function depends on its blood supply. Arresting or inhibiting the blood supply can deprive nerve tissue of oxygen and other essential nutrients to induce a metabolic block, whereby the nerve is unable to function. This block is purely a physiologic problem such that the structure of the nerve is unchanged. If the metabolic block is short in duration, it is completely reversible with no permanent effects. An example of a metabolic block is when a limb "falls asleep" (temporary numbness, paresthesia, and weakness) due to the position of a limb that restricts blood flow. Complete ischema, such as the application of a tourniquet, is followed by hyperexcitability and then loss of nerve function over 60-90 minutes. The ischema is immediately reversible when the block is released, as long as the duration of ischema is not too long, such as 1-2 hours. The first sign of impairment to intraneural blood flow occurs in the epineural blood vessels at about 20-30mm Hg pressure. At pressures of 60-80mmHg there will be complete ischemia. A metabolic block can also be induced by stretching. In animal studies, venous statis was seen at an 8% stretch and at a 15% stretch the blood supply was completely arrested. It's a frequent occurrence that patients receiving a nerve decompression see an immediate improvement in their symptoms, and this is thought to be the restoration of blood flow after a metabolic block as other forms of functional nerve impairment such as neuropraxia and axonmetesis take longer to recover.
A soldier going to battle on Pervitin usually found himself unable to perform effectively for the next day or two. Suffering from a drug hangover and looking more like a zombie than a great warrior, he had to recover from the side effects. Some soldiers turned violent, committing war crimes against civilians; others attacked their own officers. At the end of the war, it was used as part of a new drug: D-IX. Obetrol, patented by Obetrol Pharmaceuticals in the 1950s and indicated for treatment of obesity, was one of the first brands of pharmaceutical methamphetamine products. Because of the psychological and stimulant effects of methamphetamine, Obetrol became a popular diet pill in the United States in the 1950s and 1960s. Eventually, as the addictive properties of the drug became known, governments began to strictly regulate the production and distribution of methamphetamine. For example, during the early 1970s in the United States, methamphetamine became a schedule II controlled substance under the Controlled Substances Act. As of January 2013, the Desoxyn trademark had been sold to Italian pharmaceutical company Recordati.
Sources: en.wikipedia.org
It is a short synthetic peptide built from seven amino acids: methionine, glutamic acid, histidine, phenylalanine and three prolines. The sequence derives from the 4-10 fragment of adrenocorticotropic hormone with an added proline-glycine-proline tail. No plant or animal extract is involved; the material is produced by solid-phase peptide synthesis.
It was developed in the Soviet Union during the early 1980s by groups at the Institute of Molecular Genetics in Moscow. Russian approval for intranasal use followed, and it has been marketed there since. Western laboratories encountered it mainly through translated literature and, later, through online research-chemical trade.
It holds a Russian registration as a prescription nasal product but has no approval from the European Medicines Agency or the United States Food and Drug Administration. Buyers outside Russia usually receive material sold strictly for laboratory research. That distinction matters because research-grade and pharmaceutical-grade products carry different documentation and testing expectations.
It originated at the Institute of Molecular Genetics in Moscow during the 1980s. The work was carried out by a Russian research group that specialized in peptide neuropharmacology.